CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
完全上腔静脉阻塞青少年经股静脉植入静脉输液港：一例病例报告
英文原题：Femoral Venous Access Port in an Adolescent With Complete Superior Vena Cava Obstruction: A Case Report.
查看英文原题
Femoral Venous Access Port in an Adolescent With Complete Superior Vena Cava Obstruction: A Case Report.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
完全植入式静脉输液港（TIVAPs）可提供安全可靠的长期静脉通路。输液港通常植入汇入上腔静脉（SVC）的大静脉内。遗憾的是，对于SVC闭塞的患者——这是纵隔肿瘤中相当常见的并发症——将输液港植入SVC内并不可行。在一例复发原发性纵隔淋巴瘤并完全性SVC梗阻的青少年男性患者中，我们报告了通过介入放射学将输液港置入右股静脉。患者对置入耐受良好，并成功接受了CAR-T 细胞治疗。对于SVC梗阻的患者，经股静脉植入静脉输液港是可行的。
展开英文摘要原文
Totally implantable venous access ports (TIVAPs) provide safe and reliable long-term venous access. Ports are usually implanted into large veins draining into the superior vena cava (SVC). Unfortunately, in patients with SVC occlusion - a fairly common complication in mediastinal tumours - implanting ports into the SVC is not possible.
In an adolescent male with relapsed primary mediastinal lymphoma, complicated by complete SVC obstruction, we report the placement of a port into the right femoral vein by interventional radiology. The patient tolerated the insertion well and successfully received chimeric antigen receptor T-cell (CART) therapy. In patients with SVC obstruction, implanting venous ports through the femoral vein is feasible.
论文信息
- 作者
- Lian BX、Lee YY、Lee RZ、Ong SJ
- 第一作者单位
- Paediatrics, National University Hospital, Singapore, SGP.Singapore
- 通讯作者单位
- Radiology, National University of Singapore, Singapore, SGP.Singapore
- 文献类型
- 病例报告
- 期刊
- Cureus2025 Apr
- 原文标识
- PubMed 40443600 · DOI 10.7759/cureus.83169
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →